BioPortfolio - Multicenter Studies
Multicenter Studies - BioPortfolio. ... A multicenter study comparing two endometrial sampling devices--Medscand . ...
http://www.bioportfolio.com/search/Multicenter_Studies.html...
|
BioPortfolio - Multicenter Studies news
Multicenter Studies news - BioPortfolio - Indepth.
http://www.bioportfolio.com/indepth/Multicenter_Studies/news...
|
BioPortfolio - Multicenter Studies patents
Multicenter Studies patents - BioPortfolio - Indepth.
http://www.bioportfolio.com/indepth/Multicenter_Studies/pate...
|
Diatos Launches Two International Multi-center Phase II Clinical ...
5 Aug 2008 ... It is an open-label, multi-center, single-arm study conducted in eight investigational centers in Italy, France and Belgium. ...
http://www.bioportfolio.com/biotech_news/Diatos_7.htm...
|
BioPortfolio - BRCA1 breast clinical studies
From 10 studies, including this one, 83% of BRCA1 breast tumors were ER-negative , ... Clinical Trial; Multicenter Study; Randomized Controlled Trial . ...
http://www.bioportfolio.com/search/BRCA1_breast_clinical_stu...
|
BioPortfolio - Axio Research Corporation
24 Oct 2008 ... Our current work ranges from small data entry projects for biotechnology start- ups to large, multi-center studies involving hundreds of ...
http://www.bioportfolio.com/biocorporate/19031-Axio_Research...
|
BioPortfolio - Axio Research Corporation - Profile
biotechnology start-ups to large, multi-center studies involving hundreds of sites and thousands of patients. We have extensive experience in the management ...
http://www.bioportfolio.com/biocorporate/19031-Axio+Research...
|
Glucon Announces New Clinical Study Results of Aprise™ in a Poster ...
12 Jun 2006 ... OPTImus is now being evaluated in an advanced, international, multi-center clinical study. Glucon was founded by Israeli scientists, ...
http://www.bioportfolio.com/biotech_news/Glucon_2.htm...
|
Sitaxentan as an effective treatment of pulmonary arterial ...
This study is the first placebo-controlled multicenter study to evaluate a selective ETA receptor antagonist in PAH. Although the 300mg group met the ...
http://www.bioportfolio.com/LeadDiscovery/PubMed-050404.html...
|
Positive Phase I Data for Neurotech’s NT- 501 Encapsulated Cell ...
We are planning Phase II development with well-designed and controlled multi- center clinical studies to help understand the role that NT-501 will play in ...
http://www.bioportfolio.com/news/neurotech_4.htm...
|